Coverage of peptide and GLP-1 research, including on this site, regularly draws on two fairly different kinds of studies: randomized controlled trials and real-world evidence studies. Both can produce genuine, useful findings, but they answer somewhat different questions, and mixing up what each one can and can't tell you is a common way to misread a headline.
What a Randomized Controlled Trial Is Built to Do
A randomized controlled trial, or RCT, randomly assigns participants to receive either the treatment being studied or a comparator, often a placebo, discussed in more detail elsewhere on this site. Random assignment is the key feature: because who gets which treatment is left to chance rather than choice, an RCT is specifically designed to prevent the treatment and comparison groups from differing in some other hidden way that could distort the results, a problem researchers call confounding. This is why RCTs are generally considered the strongest available evidence for establishing that a treatment actually causes a specific outcome, rather than merely being associated with it.
The tradeoff is that RCTs are typically narrower than real-world use. They enroll a defined, often relatively healthy population under strict inclusion and exclusion criteria, run for a fixed and often limited duration, and monitor participants closely in ways that don't fully mirror everyday clinical practice. A drug's real-world users are frequently older, more likely to have other health conditions, and less closely monitored than an RCT's participants.
What Real-World Evidence Adds
Real-world evidence, often abbreviated RWE, comes from data generated outside a controlled trial setting: insurance claims databases, electronic health records, patient registries, and similar sources that reflect how a drug is actually being used and by whom. Because these datasets can include far larger and more diverse populations than a typical trial, and can follow people for much longer, RWE is often better positioned to detect rare side effects, long-term outcomes, and effects in patient groups, such as older adults or people with multiple health conditions, who are frequently excluded or underrepresented in RCTs.
The tradeoff runs in the opposite direction from an RCT's: because treatment assignment in RWE isn't randomized, people who receive one treatment instead of another often differ systematically from those who don't, for reasons a researcher may not be able to fully observe or measure. Statisticians use tools like propensity-score matching to try to adjust for known differences between groups, but these methods can only account for factors that were actually recorded in the data; they can't fully eliminate the risk that an unmeasured difference between groups, rather than the treatment itself, is driving an observed result.
An Example From This Site
A real-world study comparing cardiovascular outcomes between semaglutide and tirzepatide, covered elsewhere on this site, is a useful illustration of an RWE study: it draws on data from how these drugs are actually being prescribed and used, across a broader population than either drug's original approval trials, which is exactly the kind of question RWE is well suited to help answer. That doesn't make it equivalent in evidentiary strength to a head-to-head randomized trial directly comparing the two drugs, which, as of this writing, hasn't been completed.
How the FDA Uses Each
RCTs remain the standard the FDA generally requires to establish that a new drug is safe and effective enough to approve in the first place. Real-world evidence has taken on a growing, complementary role, particularly for post-market safety monitoring after a drug is already on the market, and in some cases for supporting label expansions to new indications when a dedicated RCT would be impractical or unethical to run. The two approaches aren't competitors so much as tools suited to different jobs.
The Practical Takeaway
When reading about a new peptide or GLP-1 study, whether here or elsewhere, it's worth asking which kind of study produced the finding. A randomized trial showing a drug outperforms placebo is strong evidence the drug itself caused the effect. A real-world study showing that patients taking one drug had better outcomes than patients taking another is a genuinely useful signal, especially at scale and over time, but it's a different, generally weaker kind of evidence for cause and effect, and it's worth treating conclusions drawn from it with a bit more caution until confirmed by trial data.